Novelion Therapeutics (NVLN) Reports Q4 Loss of $1.72

Novelion Therapeutics (NASDAQ: NVLN) reported Q4 EPS of ($1.72), versus ($2.26) reported last year. Revenue for the quarter came in at $37.6 million versus the consensus estimate of $40.1 million.

For earnings history and earnings-related data on Novelion Therapeutics (NVLN) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c